small molecule

DOPTELET

AVATROMBOPAG MALEATE

Loss of exclusivityJuly 2032FDA regulatory exclusivity expiry

CompanyAkaRx →View the full company profile on CliffBio

Drug detail

Brand name	DOPTELET
Active ingredient	AVATROMBOPAG MALEATE
Strength	EQ 20MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
7638536	July 2027	substance, product

Regulatory exclusivity

Code	Expires
ODE-548	July 2032
I-974	July 2028
ODE-246	June 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AkaRx